Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Biologic Drugs To Drive Pharmaceutical Market Growth

Published by: Datamonitor

Published: Oct. 3, 2006 - 9 Pages


Table of Contents


DATAMONITOR VIEW
CATALYST
SUMMARY
METHODOLOGY


ANALYSIS
The growth of biologics are set to change the pharmaceutical market in the future
Biologics will drive Big Pharma's ethical sales growth
A number of key competitive forces are driving the success biological therapies
Pharma companies are reliant on third parties to successfully penetrate the biologic sector
Competitive position of big pharma players in biologics sector
Case study: Roche alliance with Genentech has provided it with a strong foothold in the biologics sector
Amgen - the one that got away
Monoclonal antibody therapies are the key growth drivers
The evolution of antibody engineering technology is fuelling the growth of the monoclonal antibodies sector
The lifecycle of monoclonal antibody therapies are longer because of the lack of biosimilar competition

APPENDIX
Definitions
Further reading
Datamonitor Consultancy
Ask the analyst


List of Figures
Figure 1: Biologics are expected to act as the primary growth driver for the Big Pharma peer set, accounting for approximately 60% of absolute annual sales growth over 2004-10
Figure 2: Big Pharma ethical drug sales split by Biologics and Non-Biologics revenues illustrates the dominant position expected to be held by Roche in 2010
Figure 3: Technological exposure of antibody development programs is focused on fully human technologies, April 2005

Abstract

Introduction

As patent expiries take their toll on small molecule blockbuster drugs Big Pharma are turning to biologic therapies to drive future growth. Alliances and partnerships will be a key strategy in gaining access to the technology needed to successfully penetrate this market

Scope
  • An overview of Datamonitor's forecasts for the biologic therapy sales of the leading pharmaceutical companies
  • Discussion of the leading Big Pharma players operating in this area
  • A review of the evolution in antibody engineering which is currently driving the growth of this area
Highlights

Biologic therapies will drive the majority of the Big Pharma companies sales growth to 2010, based on Datamonitor's forecasts. Of these therapies monoclonal antibodies will be the key sales drivers.

Reasons to Purchase
  • Benchmark the presence of the Big Pharma companies in the biologics market place
  • Assess the key strategies that companies are using to gain access to the necessary technologies


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009